Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Immune checkpoint inhibitors don’t increase risk of death in cancer patients with COVID-19

Publish date:: August 7, 2020

Key clinical point: Treatment with immune checkpoint inhibitors does not appear to increase mortality risk among cancer patients with COVID-19.

Major finding: The mortality rate was 8% in patients with cancer and COVID-19 who received immune checkpoint inhibitors, which is comparable with the overall mortality rate previously reported among cancer patients with COVID-19 (7.6%-12%).

Study details: A study of 113 patients with COVID-19 and cancer in Europe, North America, and Australia.

Disclosures: Dr. Rogiers reported having no conflicts of interest. There was no funding disclosed for the study.

Citation:

Rogiers A et al. AACR: COVID-19 and Cancer, Abstract S02-01.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in COVID-19 Updates

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Upper GI bleeds in COVID-19 not related to increased mortality,

Obesity, hypoxia predict severity in children with COVID-19,